₹92.98
▲ +4.3 +4.85%
17 Jul 2026
BSE Listed
Phaarmasia Ltd. (523620)
Volume: 424Avg Vol 1W: 452Avg Vol 1M: 61752W Range:₹26₹131.75
Key Ratios
Checked just nowMarket Cap₹63 Cr
Current Price₹92.98
Previous Close₹88.68
High / Low (52w)₹131.75 / ₹26
Volume424
Avg Vol (1W)452
Avg Vol (1M)617
Stock P/E32.17
Book Value₹26.15
Dividend Yield0%
ROE8.93%
ROA58.48%
Revenue (TTM)—
Revenue Growth—
Profit Margin37.25%
Total Debt—
Shares Outstanding1 Cr
Face Value—
EPS (TTM)₹2.89
P/B3.56
Debt / Equity0.01
50 DMA₹92.83
200 DMA₹79.96
Day change+4.85%
Price Chart
₹92.98▲ 173.47% · 1Y
2025-07-172026-07-17
20-day avg volume: 540 shares
Pros
- Company is almost debt-free.
Cons
- Revenue fell 20% YoY.
- Company is loss-making at the latest annual result.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹8 Cr | ₹6 Cr | ₹5 Cr | ₹5 Cr | ₹7 Cr | ₹17 Cr | ₹16 Cr | ₹8 Cr |
| EBITDA | ₹0 Cr | ₹-1 Cr | ₹-1 Cr | ₹-1 Cr | ₹0 Cr | ₹2 Cr | ₹1 Cr | ₹0 Cr |
| Net Profit | ₹0 Cr | ₹-1 Cr | ₹-1 Cr | ₹-1 Cr | ₹0 Cr | ₹2 Cr | ₹16 Cr | ₹-1 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹21 Cr | ₹25 Cr | ₹25 Cr | ₹21 Cr | ₹18 Cr | ₹28 Cr | ₹31 Cr | ₹25 Cr |
| EBITDA | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹-2 Cr | ₹-1 Cr | ₹-1 Cr | ₹-2 Cr |
| Net Profit | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹-2 Cr | ₹-1 Cr | ₹-1 Cr | ₹-2 Cr |
| EPS | 0.84 | 1.14 | 0.79 | 0.46 | -2.27 | -1.84 | -0.76 | -2.33 |
Balance Sheet
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹22 Cr | ₹33 Cr | ₹34 Cr | ₹22 Cr | ₹21 Cr | ₹28 Cr | ₹31 Cr | ₹22 Cr |
| Total Liabilities | ₹10 Cr | ₹20 Cr | ₹20 Cr | ₹8 Cr | ₹9 Cr | ₹18 Cr | ₹21 Cr | ₹13 Cr |
| Equity | ₹12 Cr | ₹13 Cr | ₹13 Cr | ₹14 Cr | ₹12 Cr | ₹11 Cr | ₹10 Cr | ₹9 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Operating | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| Investing | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Financing | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Free Cash Flow | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr |
Shareholding
Promoter 73.51% Institutions 0.06% Public 26.43%
Efficiency & Working Capital
ROCE11.3%
Interest Coverage-79
Dividend Payout—
Debtor Days47 d
Inventory Days46 d
Payable Days179 d
Cash Conversion Cycle-87 d
Working Capital Days92 d
Shareholding Details
As of 2026-03-31
Promoter73.5%
FII0%
DII0.1%
Institutions0.1%
Public26.4%
Promoter Pledge0%
No. of Shareholders20,301
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 73.5% | 73.5% | 73.5% | 73.5% | 73.5% | 73.5% | 73.5% | 73.5% | 73.5% | 73.5% | 73.5% | 73.5% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0.1% | 0% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% |
| Public | 26.4% | 26.5% | 26.4% | 26.4% | 26.4% | 26.4% | 26.4% | 26.4% | 26.4% | 26.4% | 26.4% | 26.4% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 20,779 | 20,722 | 20,688 | 20,682 | 20,642 | 20,596 | 20,612 | 20,620 | 20,512 | 20,497 | 20,404 | 20,301 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Maneesh Pharmaceuticals Limited | Shareholding of Promoter and Promoter Group | 44.2% | 30,18,732 |
| Svizera Labs Pvt Ltd | Shareholding of Promoter and Promoter Group | 29.3% | 20,00,000 |
| Shubhada Godambe Atul | Public Shareholding | 1.7% | 1,18,385 |
| Madhavi Pradeep Save | Public Shareholding | 1.7% | 1,18,054 |
| Kalpana Patankar | Public Shareholding | 1.7% | 1,12,642 |
| Amruta Nishant Kalsekar | Public Shareholding | 1.5% | 1,01,512 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Maneesh Pharmaceuticals Limited | 0 | 0% | 2026-03-31 |
| Svizera Labs Pvt Ltd | 0 | 0% | 2026-03-31 |
| Shubhada Godambe Atul | 0 | 0% | 2026-03-31 |
| Kalpana Patankar | 0 | 0% | 2026-03-31 |
| Madhavi Pradeep Save | 0 | 0% | 2026-03-31 |
| Amruta Nishant Kalsekar | 0 | 0% | 2026-03-31 |
| Maneesh Pharmaceuticals Limited | 0 | 0% | 2025-12-31 |
| Svizera Labs Pvt Ltd | 0 | 0% | 2025-12-31 |
| Madhavi Pradeep Save | 0 | 0% | 2025-12-31 |
| Amruta Nishant Kalsekar | 0 | 0% | 2025-12-31 |
| Maneesh Pharmaceuticals Limited | 0 | 0% | 2025-09-30 |
| Svizera Labs Pvt Ltd | 0 | 0% | 2025-09-30 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Y N Bhaskara Rao | Whole-time Director | 2025 |
| Maneesh R Sapte | Non Executive Director | 2025 |
| Rashmi V Sapte | Non Executive Director | 2025 |
| PRAVIN M. HEGDE | Independent Director | 2025 |
| Ajit G Jamkhandikar | Independent Director | 2025 |
| Vinay Ramakant Sapte | Non Executive Director | 2025 |
| Urvashi Bhatia | Company Sec. & Compli. Officer | 2025 |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| India | ₹20 Cr | 100% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹10 | 10 | 7 | 7 |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 0 | 1 | 0 | 1 | 1 | 21 |
| 2025 | 0 | 0 | 0 | 0 | 1 | 1 |
| 2025 | 0 | 0 | 0 | 1 | 0 | 11 |
Company Information
🌐 www.phaarmasia.in ↗
📍 16 Phase III, I D A Jeedimetla, Hyderabad, Telangana, 500055
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search